Skip to main content
. 2014 Jul 11;9(7):e100230. doi: 10.1371/journal.pone.0100230

Figure 7. Ceftriaxone prevents IH-induced decrease in glutamate transporters, MAP2 and GFAP immunoreactivity.

Figure 7

EAAT1, EAAT2, GFAP and MAP2 immunoreactivity in slices exposed to 7 days RA, SH or IH in presence of 100 µM ceftriaxone. Ceftriaxone treatment prevented the decrease in EAAT1, EAAT2 in IH, and of MAP2 and GFAP in both IH and SH.